A third of the patients who received the drug were discharged from the hospital as the five-day course of treatment ended.
Among the control group, 23.3% of the patients died of COVID-19 or its complications, and average hospitalization was 17.2 days.Eyal Leshem, a senior infectious diseases doctor at Sheba Medical Center who is unconnected to the drug developer, told The Times of Israel.
A Times of Israel Community gift membership entitles your recipient to one full year of membership benefits, at a special discounted price.